NIH

AIDS Research Center on Mental Health and HIV/AIDS (P30 Clinical Trial Optional)

Funding Opportunity PAR-18-832 from the NIH Guide for Grants and Contracts. The National Institute of Mental Health (NIMH) Division of AIDS Research (DAR) encourages applications for Center Core grants (P30) to support an HIV/AIDS Research Center (ARC). The ARC is intended to provide infrastructural support that facilitates the development of high impact science in HIV/AIDS and mental health that is relevant to the NIMH mission. This FOA intends to support innovative, interdisciplinary research in several areas, including basic, neurological (i.e., neuro-HIV), behavioral and social, integrated biobehavioral, applied, clinical, translational, and implementation science.
Categories: NIH

Developmental AIDS Research Center on Mental Health and HIV/AIDS (P30 Clinical Trial Optional)

Funding Opportunity PAR-18-833 from the NIH Guide for Grants and Contracts. The National Institute of Mental Health (NIMH) Division of AIDS Research (DAR) encourages applications for Center Core grants (P30) to support Developmental AIDS Research Centers (D-ARC). The D-ARC is intended to provide infrastructural support that facilitates the development of high impact science in HIV/AIDS and mental health that is relevant to the NIMH mission. This FOA intends to support innovative, interdisciplinary research in several areas, including basic, neurological (i.e., neuro-HIV), behavioral and social, integrated biobehavioral, applied, clinical, translational, and implementation science
Categories: NIH

Development of Novel Nonsteroidal Contraceptive Methods (R61/R33 - Clinical Trial Not Allowed)

Funding Opportunity RFA-HD-19-015 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to support and facilitate multidisciplinary research approaches for the development of novel nonsteroidal contraceptive products for men and women that act prior to fertilization. This FOA aims to position innovative and validated methods for future clinical development.
Categories: NIH

Phase-out and Termination of NIGMS Participation in the NIH MERIT (R37) Program

Notice NOT-GM-18-036 from the NIH Guide for Grants and Contracts
Categories: NIH

The Role of Epitranscriptomics in Development and Disease (R21 - Clinical Trial Not Allowed)

Funding Opportunity PAR-18-831 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications from the scientific community to support outstanding research in the area of epitranscriptomics, i.e., the chemical modifications of RNA. Evidence is accumulating that RNA modifications regulate the function of both coding and noncoding RNAs, suggesting that these modifications are involved in both development, and in health and disease. Yet the extent and types of these RNA modifications as well as their roles in particular biological processes remain either poorly understood or not known. The goal of the FOA is to promote research into the role of RNA chemical modifications in the initiation and progression of various developmental processes and disease states and conditions relevant to the scientific mission of the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).
Categories: NIH

The Role of Epitranscriptomics in Development and Disease (R01 - Clinical Trial Not Allowed)

Funding Opportunity PAR-18-830 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications from the scientific community to support outstanding research in the area of epitranscriptomics, i.e., the chemical modifications of RNA. Evidence is accumulating that RNA modifications regulate the function of both coding and noncoding RNAs, suggesting that these modifications are involved in both development, and in health and disease. Yet the extent and types of these RNA modifications as well as their roles in particular biological processes remain either poorly understood or not known. The goal of the FOA is to promote research into the role of RNA chemical modifications in the initiation and progression of various developmental processes and disease states and conditions relevant to the scientific mission of the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), the National Cancer Institute (NCI), and the National Eye Institute (NEI).
Categories: NIH

Early Registration Ends June 29 for Fall 2018 NIH Regional Seminar in San Francisco, CA

Notice NOT-OD-18-192 from the NIH Guide for Grants and Contracts
Categories: NIH

Immune Mechanisms at the Maternal-Fetal Interface (R01 Clinical Trial Optional)

Funding Opportunity RFA-AI-18-023 from the NIH Guide for Grants and Contracts. This initiative will support research to determine the roles and interactions of immune cells at the maternal-fetal interface throughout pregnancy, including mechanisms of responses to vaccination and infection that protect the fetus and that may influence fetal immune system development.
Categories: NIH

NIAID Policy for T32 and T35 Competing Renewal Application Submissions

Notice NOT-AI-18-040 from the NIH Guide for Grants and Contracts
Categories: NIH

NCCIH Natural Product Early Phase Clinical Trial Award (R33 Clinical Trial Required)

Funding Opportunity PAR-18-828 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages applications for investigator-initiated early phase clinical trials of natural products (i.e., botanicals, dietary supplements, and probiotics), which have a strong scientific premise to justify further clinical testing. Under this FOA, trials must be designed so that results, whether positive or negative, will provide information of high scientific utility and will support decisions about further development or testing of the natural product. This FOA will provide up to 3 years support for studies to replicate the impact of the natural product on the biological signature(s) when used by humans and assess whether there is an association between the degree of the impact on the biological signature and functional or clinical outcomes in a patient population. Applications can design studies to determine how to optimize the impact of the natural product on the biological signature by (1) optimizing the delivery of the natural product by dose or formulation; (2) combine the natural product with another treatment approach that is known to impact the same biological signature; or (3) study the impact of the natural product in a target population that is more responsive. Clinical trials submitted under this FOA are expected to be hypothesis based, milestone-driven, and directly related to the research priorities and mission of NCCIH. This R33 funding mechanism is intended to accelerate the translation of emerging basic science findings about natural products into early stage clinical testing to determine whether continued clinical research is warranted. This FOA will not support efficacy or effectiveness trials, nor will it support trials to test natural products for the treatment or prevention of cancer.
Categories: NIH

NCCIH Natural Product Early Phase Clinical Trial Phased Innovation Award (R61/R33 Clinical Trial Required)

Funding Opportunity PAR-18-829 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages applications for investigator-initiated early phase clinical trials of natural products (i.e., botanicals, dietary supplements, and probiotics), which have a strong scientific premise to justify further clinical testing. Under this FOA, trials must be designed so that results, whether positive or negative, will provide information of high scientific utility and will support decisions about further development or testing of the natural product. This FOA will provide up to two years (R61 phase) of support for milestone-driven testing of bioavailability, pharmacokinetics, and assessment of the natural products effect (i.e., measure of mechanism of action) when used by humans on a biological signature(s). If milestones in the R61 phase are achieved, up to 3 years of additional support (R33 phase) may be awarded to replicate the impact of the natural product on the biological signature(s) when used by humans and assess whether there is an association between the degree of the impact on the biological signature and functional or clinical outcomes in a patient population. Applications can design R33 studies to determine how to optimize the impact of the natural product on the biological signature by (1) optimizing the delivery of the natural product by dose or formulation; (2) combine the natural product with another treatment approach that is known to impact the same biological signature; or (3) study the impact of the natural product in a target population that is more responsive. Clinical trials submitted under this FOA are expected to be hypothesis based, milestone-driven, and directly related to the research priorities and mission of NCCIH. This R61/R33 funding mechanism is intended to accelerate the translation of emerging basic science findings about natural products into early-stage clinical testing to determine whether continued clinical research is warranted. This FOA will not support efficacy or effecti
Categories: NIH
Syndicate content